Does the Benefit of Cholesterol-Lowering of a Given Magnitude Depend on the Drug Intervention Used?

Elani Streja^{1

2}, Dan Streja³

Affiliations

¹ Division of Nephrology and Hypertension, Department of Medicine, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine Medical Center, Orange, CA (E.S.).
² Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA (E.S.).
³ Division of Endocrinology, Diabetes and Metabolism, David Geffen School of Medicine at UCLA, Greater Los Angeles VA Healthcare System, West Los Angeles VA Medical Center (D.S.).

Free article

Editorial

Elani Streja et al. Circ Cardiovasc Qual Outcomes. 2019 Aug.

Free article

. 2019 Aug;12(8):e005599.

doi: 10.1161/CIRCOUTCOMES.119.005599. Epub 2019 Aug 15.

Elani Streja^{1

2}, Dan Streja³

¹ Division of Nephrology and Hypertension, Department of Medicine, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine Medical Center, Orange, CA (E.S.).
² Nephrology Section, Tibor Rubin Veterans Affairs Medical Center, Long Beach, CA (E.S.).
³ Division of Endocrinology, Diabetes and Metabolism, David Geffen School of Medicine at UCLA, Greater Los Angeles VA Healthcare System, West Los Angeles VA Medical Center (D.S.).

No abstract available

Keywords: Editorials; cholesterol; epidemiological studies; ezetimibe; proprotein convertase.

Comment on

More- Versus Less-Intensive Lipid-Lowering Therapy.
Toyota T, Morimoto T, Yamashita Y, Shiomi H, Kato T, Makiyama T, Nakagawa Y, Saito N, Shizuta S, Ono K, Kimura T. Toyota T, et al. Circ Cardiovasc Qual Outcomes. 2019 Aug;12(8):e005460. doi: 10.1161/CIRCOUTCOMES.118.005460. Epub 2019 Aug 15. Circ Cardiovasc Qual Outcomes. 2019. PMID: 31412729